# **Cancer Cell**

### **Caloric Restriction Mimetics Enhance Anticancer** Immunosurveillance

### **Highlights**

- Short-term fasting improves anticancer chemotherapy
- Treatment with caloric restriction mimetics (CRMs) inhibits tumor growth in vivo
- CRMs trigger an autophagy-dependent anticancer immune response
- CRMs deplete regulatory T Cells from tumor bed

### **Authors**

Federico Pietrocola, Jonathan Pol, Erika Vacchelli, ..., Beth Levine, Josef M. Penninger, Guido Kroemer

#### Correspondence

kroemer@orange.fr

### In Brief

Pietrocola et al. show that short-term fasting or autophagy-inducing caloric restriction mimetics, such as hydroxycitrate and spermidine, improves the antitumor efficacy of chemotherapy in vivo. The effect is specific for autophagy-competent tumors and depends on regulatory T cell depletion from the tumor bed.



## Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance

Federico Pietrocola,<sup>1,2,3,23</sup> Jonathan Pol,<sup>1,2,3,5,23</sup> Erika Vacchelli,<sup>1,2,3</sup> Shuan Rao,<sup>6</sup> David P. Enot,<sup>1,7</sup> Elisa E. Baracco,<sup>1,2,3,4</sup> Sarah Levesque,<sup>1,2,3,4</sup> Francesca Castoldi,<sup>1,2,3,4,8</sup> Nicolas Jacquelot,<sup>1,4,9,10</sup> Takahiro Yamazaki,<sup>1,4,9,10</sup> Laura Senovilla,<sup>1,2,3,5</sup> Guillermo Marino,<sup>1,2,3</sup> Fernando Aranda,<sup>1,2,3</sup> Sylvère Durand,<sup>1,7</sup> Valentina Sica,<sup>1,2,3,4</sup> Alexis Chery,<sup>1,7</sup> Sylvie Lachkar,<sup>1,2,3,4</sup> Verena Sigl,<sup>6</sup> Norma Bloy,<sup>1,2,3,4</sup> Aitziber Buque,<sup>1,2,3,4</sup> Simonetta Falzoni,<sup>11</sup> Bernhard Ryffel,<sup>12,13</sup> Lionel Apetoh,<sup>14,15,16</sup> Francesco Di Virgilio,<sup>11</sup> Frank Madeo,<sup>17,18</sup> Maria Chiara Maiuri,<sup>1,2,3,4</sup> Laurence Zitvogel,<sup>1,4,9,10</sup> Beth Levine,<sup>19</sup> Josef M. Penninger,<sup>6,24</sup> and Guido Kroemer<sup>1,2,3,5,7,20,21,22,24,\*</sup> <sup>1</sup>Gustave Roussy Cancer Campus, 94800 Villejuif, France <sup>2</sup>INSERM, U1138, 75006 Paris, France <sup>3</sup>Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, 75006 Paris, France <sup>4</sup>Université Paris-Sud/Paris-Saclay, Faculté de Médecine, 94276 Kremlin-Bicêtre, France <sup>5</sup>Université Paris Descartes/Paris V, Sorbonne Paris Cité, 75006 Paris, France <sup>6</sup>Institute for Molecular Biotechnology of the Austrian Academy of Sciences, 1030 Vienna, Austria <sup>7</sup>Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, 94800 Villejuif, France <sup>8</sup>Sotio a.c., 17000 Prague, Czech Republic <sup>9</sup>INSERM U1015, Gustave Roussy Cancer Campus, 94800 Villejuif, France <sup>10</sup>Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, 94800 Villejuif, France <sup>11</sup>Department of Morphology, Surgery and Experimental Medicine University of Ferrara, 44121 Ferrara, Italy <sup>12</sup>UMR7355, CNRS and University, 45067 Orléans, France <sup>13</sup>Institute of Infectious Disease and Molecular Medicine, University of Cape Town, 7925 Cape Town, South Africa 14INSERM, U866, 21078 Dijon, France <sup>15</sup>Faculté de Médecine, Université de Bourgogne, 21078 Dijon, France <sup>16</sup>Centre Georges François Leclerc, 21000 Dijon, France <sup>17</sup>Institute of Molecular Biosciences, NAWI Graz, University of Graz, Humboldtstraße 50, 8010 Graz, Austria <sup>18</sup>BioTechMed-Graz, Humboldtstraße 50, 8010 Graz, Austria <sup>19</sup>Department of Internal Medicine, Center for Autophagy Research, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX 73590, USA <sup>20</sup>Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, 75015 Paris, France <sup>21</sup>Department of Women's and Children's Health, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden <sup>22</sup>INSERM U1138, Centre de Recherche des Cordeliers, 75006 Paris, France <sup>23</sup>Co-first author <sup>24</sup>Co-senior author \*Correspondence: kroemer@orange.fr http://dx.doi.org/10.1016/j.ccell.2016.05.016

#### SUMMARY

Caloric restriction mimetics (CRMs) mimic the biochemical effects of nutrient deprivation by reducing lysine acetylation of cellular proteins, thus triggering autophagy. Treatment with the CRM hydroxycitrate, an inhibitor of ATP citrate lyase, induced the depletion of regulatory T cells (which dampen anticancer immunity) from autophagy-competent, but not autophagy-deficient, mutant KRAS-induced lung cancers in mice, thereby improving anticancer immunosurveillance and reducing tumor mass. Short-term fasting or treatment with several chemically unrelated autophagy-inducing CRMs, including hydroxycitrate and spermidine, improved the inhibition of tumor growth by chemotherapy in vivo. This effect was only observed for autophagy-competent tumors, depended on the presence of T lymphocytes, and was accompanied by the depletion of regulatory T cells from the tumor bed.

#### Significance

Fasting can improve the efficacy of anticancer chemotherapy. We show here that this effect involves induction of autophagy in malignant cells, as well as an anticancer immune response. Fasting can be replaced by the administration of caloric restriction mimetics (CRMs), which—without causing weight loss—improve the efficacy of chemotherapy as well. The tumor growth-inhibitory effects of hydroxycitrate were epistatic to the inhibition of regulatory T cells. Altogether, our results reveal a common mechanism for the cancer protective properties of CRMs and point to the possibility of stimulating anticancer immune responses by inducing autophagy with well-tolerable CRMs in vivo. Download English Version:

# https://daneshyari.com/en/article/2106711

Download Persian Version:

https://daneshyari.com/article/2106711

Daneshyari.com